Virpax Pharmaceuticals(VRPX) - 2023 Q2 - Quarterly Report

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 1055 Westlakes Drive, Suite 300 Berwyn, PA 19312 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from_____ to______ Commission File Number: 001-40064 VIRPAX PHARMACEUTICALS, INC. (Exact name of registrant as specified in t ...